Averin Capital Acquisition Corp. Appoints Akiko Moni Miyashita to Board
Averin Capital Acquisition Corp. appointed Akiko Moni Miyashita to its Board of Directors, effective May 28, 2026. Ms. Miyashita brings over 25 years of experience in strategy, finance, and corporate development, with expertise in healthcare, life sciences, technology, and global markets. Her background includes founding Beacon Hill Strategy Group, serving on the board of Halozyme Therapeutics, and executive roles at Valo Health, McKinsey & Company, Innosight LLC, and IBM. In connection with her appointment, she entered into standard director agreements, including a joinder to a Letter Agreement and a Registration Rights Agreement.
Key Highlights
- Averin Capital Acquisition Corp. appointed Akiko Moni Miyashita to its Board of Directors, effective May 28, 2026.
- Ms. Miyashita will serve as a member of the first class of directors.
- She is the Founder of Beacon Hill Strategy Group, advising on growth strategy, M&A, and AI-enabled transformation.
- Ms. Miyashita previously served on the board of Halozyme Therapeutics, Inc. from May 2022 to May 2026.
- Her experience includes executive roles at Valo Health, McKinsey & Company, Innosight LLC, and IBM.
- She has over 25 years of experience in strategy, finance, and corporate development across healthcare, life sciences, and technology.
- Ms. Miyashita signed a joinder to a Letter Agreement and a Registration Rights Agreement.
Price Impact
More from ACAAU
ACAAU Q2 Net Income $2.36M; Going Concern Doubt Raised
Averin Capital Q1 Net Income $832,500; Going Concern Doubt Noted
Averin Capital Acquisition Corp. to Commence Separate Trading of Class A Shares and Warrants on April 10, 2026